These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33125664)

  • 21. European pharmacovigilance: increasingly outsourced to drug companies.
    Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.
    Engel P; Almas MF; De Bruin ML; Starzyk K; Blackburn S; Dreyer NA
    Br J Clin Pharmacol; 2017 Apr; 83(4):884-893. PubMed ID: 27780289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A decade of collaboration in medicines regulation: healthcare professionals engaging with the European Medicines Agency.
    Silva I; Gabrielli G; Garcia Burgos J; Moulon I; Calvo Rojas G; Jaeger U; Giuliani R
    Front Med (Lausanne); 2024; 11():1399947. PubMed ID: 38898937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
    Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stakeholders' engagement in co-producing policy-relevant knowledge to facilitate employment for persons with developmental disabilities.
    Khayatzadeh-Mahani A; Wittevrongel K; Petermann L; Graham ID; Zwicker JD
    Health Res Policy Syst; 2020 Apr; 18(1):39. PubMed ID: 32303228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healthcare stakeholders' perceptions and experiences of factors affecting the implementation of critical care telemedicine (CCT): qualitative evidence synthesis.
    Xyrichis A; Iliopoulou K; Mackintosh NJ; Bench S; Terblanche M; Philippou J; Sandall J
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD012876. PubMed ID: 33599282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additional risk minimisation measures in the EU - are they eligible for assessment?
    Zomerdijk IM; Trifirò G; Sayed-Tabatabaei FA; Sturkenboom MC; Straus SM
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1046-53. PubMed ID: 23946274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving the Safety of Medicines in the European Union: From Signals to Action.
    Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
    Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Network Engagement in Action: Stakeholder Engagement Activities to Enhance Patient-centeredness of Research.
    Poger JM; Mayer V; Duru OK; Nauman B; Holderness H; Warren N; Vasquez C; Bibi S; Rasmussen-Torvik LJ; Hosseinian Z; Shi L; Wallace J; Goytia CN; Horowitz CR; Kraschnewski JL
    Med Care; 2020 Jun; 58 Suppl 6 Suppl 1(Suppl 6 1):S66-S74. PubMed ID: 32412955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance and image enhancing drug interventions aimed at increasing knowledge among healthcare professionals (HCP): reflections on the implementation of the Dopinglinkki e-module in Europe and Australia in the HCP workforce.
    Atkinson AM; van de Ven K; Cunningham M; de Zeeuw T; Hibbert E; Forlini C; Barkoukis V; Sumnall HR
    Int J Drug Policy; 2021 Sep; 95():103141. PubMed ID: 33549466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mapping Stakeholder Perspectives on Engagement in Concussion Research to Theory.
    Hunt C; de Saint-Rome M; Di Salle C; Michalak A; Wilcock R; Baker A
    Can J Neurol Sci; 2020 Mar; 47(2):202-209. PubMed ID: 31967536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical Care Network in the State of Qatar.
    Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
    Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engaging Healthcare Staff and Stakeholders in Healthcare Simulation Modeling to Better Translate Research Into Health Impact: A Systematic Review.
    Zabell T; Long KM; Scott D; Hope J; McLoughlin I; Enticott J
    Front Health Serv; 2021; 1():644831. PubMed ID: 36926474
    [No Abstract]   [Full Text] [Related]  

  • 35. Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments.
    McGettigan P; Alonso Olmo C; Plueschke K; Castillon M; Nogueras Zondag D; Bahri P; Kurz X; Mol PGM
    Drug Saf; 2019 Nov; 42(11):1343-1351. PubMed ID: 31302896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using Stakeholder Engagement to Overcome Barriers to Implementing Patient-reported Outcomes (PROs) in Cancer Care Delivery: Approaches From 3 Prospective Studies.
    Stover AM; Tompkins Stricker C; Hammelef K; Henson S; Carr P; Jansen J; Deal AM; Bennett AV; Basch EM
    Med Care; 2019 May; 57 Suppl 5 Suppl 1():S92-S99. PubMed ID: 30985602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stakeholder engagement from problem analysis to implementation strategies for a patient-reported experience measure in disability care: A qualitative study on the process and experiences.
    van Rooijen M; Lenzen S; Dalemans R; Beurskens A; Moser A
    Health Expect; 2021 Feb; 24(1):53-65. PubMed ID: 33125177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe.
    Jouaville LS; Paul T; Almas MF
    Pharmacoepidemiol Drug Saf; 2021 Sep; 30(9):1143-1152. PubMed ID: 34092001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder.
    Agyemang E; Bailey L; Talbot J
    Pharmaceut Med; 2017; 31(2):101-112. PubMed ID: 28413313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Experiences of Stakeholders Using Social Media as a Tool for Health Service Design and Quality Improvement: A Scoping Review.
    Walsh L; Hyett N; Juniper N; Li C; Hill S
    Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.